Product Description
Mechanisms of Action: PLK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00536835 |
PLK107427 | P1 |
Completed |
Lymphoma, Non-Hodgkin |
2009-09-29 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/19/2023 |
PubMed |
The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells. |
|
09/19/2023 |
PubMed |
PLK1 Regulates MicroRNA Biogenesis through Drosha Phosphorylation. |
|
08/01/2023 |
PubMed |
BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines. |